Order Article Reprints

Roblin X, Duru G, Papamichael K, Cheifetz AS, Kwiatek S, Berger A-E, Barrau M, Waeckel L, Nancey S, Paul S. Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease. Journal of Clinical Medicine. 2023; 12(10):3395. https://doi.org/10.3390/jcm12103395

Roblin, Xavier, Gérard Duru, Konstantinos Papamichael, Adam S. Cheifetz, Sandy Kwiatek, Anne-Emmanuelle Berger, Mathilde Barrau, Louis Waeckel, Stephane Nancey, and Stephane Paul. 2023. "Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease" Journal of Clinical Medicine 12, no. 10: 3395. https://doi.org/10.3390/jcm12103395

Roblin, X., Duru, G., Papamichael, K., Cheifetz, A. S., Kwiatek, S., Berger, A.-E., Barrau, M., Waeckel, L., Nancey, S., & Paul, S. (2023). Development of Antibodies to Ustekinumab Is Associated with Loss of Response in Patients with Inflammatory Bowel Disease. Journal of Clinical Medicine, 12(10), 3395. https://doi.org/10.3390/jcm12103395